Category Archives: Business of Biotech

Are You Ready To Go Beyond The Cutting Edge At BIO 2016?

biocon

In an April 18 blog posted on Life Science Leader, Rob Wright outlined the essential components of a compelling and educational panel for the 2016 BIO International Convention. Wright will be moderating a Super Session panel on Tuesday, June 7 from 11:15 AM–12:30 PM called Beyond the Cutting Edge: How to Enable Life Science Organizations Today for the Societal Challenges of Tomorrow.  The session will focus on innovation and knowledge transfer opportunities across disciplines as well as industries. Wright asks readers to provide Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Do Outcomes Matter When There Is Chronic Misalignment?

synthetic biology

This piece by Allan L. Shaw was originally published in Life Science Leader. With over $3 trillion in annual healthcare spending, a relatively young population, and shorter life expectancies than other western nations, one would think there would be vast opportunities for the U.S. healthcare industry to rein in costs, weed out inefficiency, and improve outcomes. Instead of yielding to “regression toward the mean,” however, the highest global per capita healthcare machine marches to 20 Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Biomarkets: Looking For The Hole In The Donut

synthetic biology

This piece by Allan L. Shaw was originally published in Life Science Leader. The biopharma sector has enjoyed increased market success over the last few years. And while some may be tempted to bask in the optimistic “bio-euphoria,” others question whether the industry might be in the midst of a market bubble. What led to this current period of biopharma success, despite the industry’s inherent risks (e.g. scientific, clinical, regulatory, and commercial)? Several factors contributed Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Warning: Don’t Let Bio-Euphoria Distract You from Being Disciplined

DNA

This piece by Allan L. Shaw was originally published in Life Science Leader. We currently in a period I call “bio-euphoria,” in which the biopharmaceutical industry is experiencing growth in almost every area from market performance to patient-focused legislation. In parallel to this positive momentum, there has also been a notable shift in management and operational strategy by Big Pharma companies in an attempt to keep evolving with the market. These companies are taking creative Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Discover Trends and Investment Opportunities at the BIO Investor Forum

hyde pier

The 2015 BIO Investor Forum in San Francisco is shaping up to be a must-attend event for private equity and public investors, research analysts, and industry executives focused on investment and business development opportunities in the life sciences. The Forum will include candid fireside chats between biopharma CEOs, analysts, and other industry experts. Come hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2016. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,